---
title: "Metabolic Disease Biotechnology Industry"
description: "Metabolic disease biotechnology companies develop treatments for obesity, diabetes, fatty liver disease and rare metabolic disorders. Key measures."
canonical: https://www.getswoopr.com/stocks/industries/health-care/metabolic-disease-biotechnology/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Metabolic Disease Biotechnology Industry

## Direct Answer

Metabolic disease biotechnology companies develop treatments for obesity, diabetes, fatty liver disease and rare metabolic disorders. Many are small and depend on trial results, while a few large drugs shape the market.

## Industry Overview

Metabolic Disease Biotechnology sits within the health care sector. The first numbers to compare across companies here are clinical trial readouts and endpoints, cash runway and partnering deals. The outside forces that move them are listed under Primary Macro Drivers.

## Key Industry Metrics

- **Clinical trial readouts and endpoints**: Results from trials, measured against goals such as weight loss, blood sugar or liver fat. Whether the main endpoint was met and how large the effect was drive expectations for approval and use.
- **Cash runway**: Months of operating spending covered by cash on hand. Developers without sales rely on financing, so a short runway raises the odds of dilution.
- **Partnering deals**: Licensing or collaboration agreements with larger drugmakers, usually paying upfront and milestone fees. Partnerships validate science and fund development, but terms show how much value stays with the developer.
- **Manufacturing supply**: Ability to produce enough drug, especially injectables, for trials and sales. Supply shortages can limit uptake, so look for contracts or capacity plans.
- **Sales of approved products**: Revenue from marketed drugs. For small companies, early sales show launch traction; for those without products the measure is empty and the pipeline matters more.

## Primary Macro Drivers

- **Obesity and fatty liver disease prevalence**: More people with obesity and liver disease enlarges the potential market, which supports interest from partners and investors in successful candidates.
- **Payer coverage of weight-loss drugs**: When insurers pay for weight-loss drugs, patient access widens, which can set the sales potential of newer drugs entering the class.
- **Success of leading injectable drugs**: A leading injectable drug proves demand and sets benchmarks for efficacy and tolerability that newer candidates are compared against.
- **Regulatory guidance on endpoints**: Guidance on acceptable endpoints decides what trial results regulators will accept, which sets trial design, cost and timing.

## Major Risks

- **Trial failures and safety**: A failed study or a safety problem can remove most of a small company's value; watch trial readouts, safety updates and company disclosures on endpoints.
- **Funding and dilution**: Small developers often raise cash by issuing shares, which dilutes holders; watch cash runway and the size of recent offerings.
- **Competition from large incumbents**: Large incumbents can use scale, supply and cash to outcompete newcomers; watch competitor data and partnering activity.
- **Reimbursement limits**: Limited coverage restricts how many patients can use a drug, lowering expected sales; watch payer decisions and company comments on access.

## Industry Characteristics

| Characteristic | Profile |
| --- | --- |
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |

## Companies Associated with Metabolic Disease Biotechnology

The SEC's Standard Industrial Classification has no code that describes metabolic disease biotechnology as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.

| Company | SEC classification | Revenue | Growth | Net margin | Year |
| --- | --- | --- | --- | --- | --- |
| [Madrigal Pharmaceuticals, Inc.](https://www.getswoopr.com/stocks/companies/madrigal-pharmaceuticals-inc/) | Pharmaceutical Preparations | $958 million | 432.1% | -30.1% | FY 2025 |
| [Altimmune, Inc.](https://www.getswoopr.com/stocks/companies/altimmune-inc/) | Pharmaceutical Preparations | $41,000 | 105.0% | -214861.0% | FY 2025 |

Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the [company directory](https://www.getswoopr.com/stocks/companies/) and the [health care hub](https://www.getswoopr.com/stocks/industries/health-care/).

## Where to Go Next

The Metabolic Disease Biotechnology guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.

### More in Health Care

- [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/)
- [mRNA Therapeutics](https://www.getswoopr.com/stocks/industries/health-care/mrna-therapeutics/)
- [Medicare Advantage](https://www.getswoopr.com/stocks/industries/health-care/medicare-advantage/)
- [Neuroscience Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/neuroscience-biotechnology/)
- [Medical Supplies](https://www.getswoopr.com/stocks/industries/health-care/medical-supplies/)
- [Obesity & GLP-1 Therapeutics](https://www.getswoopr.com/stocks/industries/health-care/obesity-and-glp-1-therapeutics/)
- [Medical Imaging Equipment](https://www.getswoopr.com/stocks/industries/health-care/medical-imaging-equipment/)
- [Oncology Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/oncology-biotechnology/)
- [Medical Devices](https://www.getswoopr.com/stocks/industries/health-care/medical-devices/)

### Put it to work

- [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)
- [Company research](https://www.getswoopr.com/stocks/companies/)
- [All industries](https://www.getswoopr.com/stocks/industries/)

## Frequently Asked Questions

What are the main KPIs for the Metabolic Disease Biotechnology industry?

Key performance indicators for the Metabolic Disease Biotechnology industry include: Clinical trial readouts and endpoints, Cash runway, Partnering deals, Manufacturing supply, Sales of approved products. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.

How cyclical is the Metabolic Disease Biotechnology industry?

The Metabolic Disease Biotechnology industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.

What are the biggest risks in the Metabolic Disease Biotechnology industry?

The primary risks for Metabolic Disease Biotechnology companies include: Trial failures and safety, Funding and dilution, Competition from large incumbents, Reimbursement limits. Investors should assess each company's exposure to these factors and its track record of navigating them.

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).